NextCure, Inc. (NASDAQ:NXTC - Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 36,303 shares of the business's stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $4.94 per share, for a total transaction of $179,336.82. Following the completion of the transaction, the insider directly owned 722,419 shares in the company, valued at $3,568,749.86. The trade was a 5.29% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Thursday, July 30th, Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock. The stock was purchased at an average cost of $4.93 per share, with a total value of $1,443,750.50.
- On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, with a total value of $17,050.00.
- On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The stock was purchased at an average price of $4.95 per share, for a total transaction of $31,680.00.
- On Monday, July 27th, Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock. The shares were purchased at an average price of $5.00 per share, for a total transaction of $38,990.00.
NextCure Stock Up 6.3%
NASDAQ:NXTC opened at $4.40 on Tuesday. The stock has a market cap of $15.88 million, a price-to-earnings ratio of -0.26 and a beta of 1.26. The company's 50 day moving average price is $3.42 and its 200-day moving average price is $8.59. NextCure, Inc. has a 52 week low of $1.55 and a 52 week high of $15.74.
NextCure (NASDAQ:NXTC - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping analysts' consensus estimates of ($2.10) by $0.23. As a group, sell-side analysts anticipate that NextCure, Inc. will post -7.89 earnings per share for the current year.
Analyst Upgrades and Downgrades
NXTC has been the subject of several recent analyst reports. Weiss Ratings cut NextCure from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, July 7th. Wall Street Zen cut NextCure from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Zacks Research raised NextCure from a "strong sell" rating to a "hold" rating in a research report on Thursday, June 11th. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of NextCure in a report on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, NextCure presently has a consensus rating of "Hold" and a consensus price target of $19.00.
View Our Latest Stock Analysis on NextCure
Hedge Funds Weigh In On NextCure
Several hedge funds and other institutional investors have recently modified their holdings of NXTC. Geode Capital Management LLC boosted its position in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company's stock worth $329,000 after purchasing an additional 3,636 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company's stock valued at $477,000 after purchasing an additional 5,300 shares during the period. Marshall Wace LLP bought a new position in shares of NextCure in the 4th quarter worth approximately $160,000. Millennium Management LLC purchased a new position in shares of NextCure in the fourth quarter worth approximately $185,000. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of NextCure by 28.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company's stock worth $3,509,000 after buying an additional 55,412 shares during the last quarter. 42.65% of the stock is owned by institutional investors.
NextCure Company Profile
(
Get Free Report)
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure's research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company's pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
